Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 19Thoracic 12Genitourinary 10Head & Neck 8Endocrine 6Breast 6Gynecologic 5CNS 4Sarcoma 3NET 3Dermatologic 3Tumor-Agnostic 2Lymphoid 1

Conditions

Neoplasms 391Neoplasm Metastasis 103Carcinoma 26Carcinoma, Squamous Cell 15Adenocarcinoma 15Neoplasms, Unknown Primary 11Neoplasms by Site 2

Interventions

Nivolumab 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms by Site × Tumor-Agnostic × Clear all
NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

NCT03656718 2025-11-12

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Bristol-Myers Squibb

Phase 1/2 Completed
139 enrolled 26 charts
Tumor-Agnostic

Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡